IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Covestor Ltd

Covestor Ltd raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 34.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 246 shares of the medical research company’s stock after purchasing an additional 63 shares during the quarter. Covestor Ltd’s holdings in IQVIA were worth $59,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of IQV. First Foundation Advisors grew its position in shares of IQVIA by 3.8% during the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after buying an additional 43 shares in the last quarter. Invera Wealth Advisors LLC increased its position in shares of IQVIA by 0.3% in the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after purchasing an additional 46 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of IQVIA by 0.3% during the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after purchasing an additional 48 shares during the last quarter. Continuum Advisory LLC grew its stake in IQVIA by 3.3% in the second quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock worth $325,000 after purchasing an additional 49 shares in the last quarter. Finally, Clear Harbor Asset Management LLC increased its holdings in IQVIA by 1.3% in the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock valued at $941,000 after buying an additional 50 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Activity

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is currently owned by company insiders.

IQVIA Price Performance

Shares of NYSE:IQV opened at $202.94 on Friday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market capitalization of $36.83 billion, a PE ratio of 26.63, a price-to-earnings-growth ratio of 2.20 and a beta of 1.51. The stock has a fifty day moving average of $228.86 and a 200-day moving average of $228.77. IQVIA Holdings Inc. has a one year low of $200.20 and a one year high of $261.73.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Truist Financial reduced their target price on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Argus upgraded IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research note on Friday, November 1st. BTIG Research cut their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, Redburn Atlantic began coverage on IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 target price on the stock. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $259.13.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.